Medical World News

[Preciouslife1]

IPIX … Brilacidin is the only non-peptidic defensin-mimetic drug candidate in the world currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19. Additionally, Brilacidin has shown potent inhibition in vitro against different strains of coronaviruses and alphaviruses (with lab testing against other virus families also underway), supporting Brilacidin’s potential to be developed as a broad spectrum antiviral.

Additionally, physicians ability to manage the severe side effects of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) not only improves with experience but is being expedited through studies promoting early use of steroids or monoclonal antibodies such as tocilizumab or lenzilumab (Kite’s ZUMA-19, KTE-C19)